CompletedNot Applicable

Interleukin-6 and Thyroid Dysfunction in Hemodialysis Patients

Indonesia65 participantsStarted 2023-11-14

Plain-language summary

Chronic kidney disease (CKD) is often associated with multiorgan complications, including thyroid hormone dysfunction. Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been proposed as a marker of inflammation that may contribute to these alterations. The main question it aims to answer is: Is there an association between interleukin-6 and thyroid hormone dysfunction in patients with chronic kidney disease (CKD) Blood samples will be collected and analyzed from 65 patients who have undergone hemodialysis for at least 3 months.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 21 Years Old and above * Patients with ESRD who have undergone hemodialysis for ≥ 3 months and are in stable condition. * Patients are able to communicate and respond to questions appropriately * Patients are willing to participate in the study. Exclusion Criteria: * ESRD patients undergoing hemodialysis who have been diagnosed with underlying thyroid disorders or thyroid malignancy. * Patients with a history of thyroid surgery or any intervention involving the thyroid gland. * Patients with a family history of thyroid disorders. * Patients taking medications that affect thyroid function or using antioxidant drugs. * Patients with infection or sepsis.

What they're measuring

Correlation between serum Interleukin-6 (IL-6) concentration and serum Thyroid-Stimulating Hormone (TSH) levels

Timeframe: At baseline, during routine hemodialysis visit (prior to any study-specific intervention)

Trial details

NCT IDNCT07328113

SponsorDr. Soetomo General Hospital

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2024-03-31